MitoRx Therapeutics is a longevity biotech company based from Oxford and Exeter, UK. Its first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases, focusing internally on 3 rare indications and partnering on broader indications.

MitoRx proprietary technology exploits an endogenous mechanism which mediates sulfide-signaling, having the effect of substrate replenishment in states of trans-sulfuration deficiency omnipresent in several diseases and certain medical conditions, resulting in the restoration of adaptive metabolism. The company is developing a pipeline of pre-clinical programs to progress to the clinic. Built around the pioneer of mitochondrial-targeted sulfide donor technology, the team is specialized in rare diseases acceleration and IP strategy. 

MitoRx Therapeutics Executive Team

• Glyn Edwards, Chairman

• Jon Rees, CEO and Co-founder

• Norman Law, CTO, Head of IP and Co-founder

• Chris Charman, Chief Development Officer

• Matt Whiteman, Inventor, Co-founder and CSO